Skip to main content
SpringerLink
Log in

Krebsimmuntherapie beim nicht-kleinzelligen Lungenkarzinom

Atezolizumab - auch im frühen Stadium eine effektive Option

  • InfoPharm
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Felip E et al, World Congress on Lung Cancer (WCLC) 2022, Orale Präsentation, PL03.09

  2. Felip E et al, European Lung Cancer Congress (ELCC), #80O, Ann Oncol 2022, 33 (Suppl_2): S71-78

Download references

Author information

Authors and Affiliations

  1. Pressebüro, Auf den Äckern 15, 59394, Nordkirchen, Deutschland

    Birgit-Kristin Pohlmann

Authors
  1. Birgit-Kristin Pohlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pohlmann, BK. Atezolizumab - auch im frühen Stadium eine effektive Option. Pneumo News 15, 48–50 (2023). https://doi.org/10.1007/s15033-023-3467-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-023-3467-7

Search

Navigation